Telix Pharmaceuticals (TLX) Other Non-Current Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Other Non-Current Liabilities for 3 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Non-Current Liabilities fell 60.95% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (down 60.95% YoY), while the FY2025 annual figure was $3.5 million, down 58.77% from the prior year.
• Other Non-Current Liabilities declined to $3.5 million in Q4 2025 per TLX's latest filing, from $9.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $9.0 million in Q4 2024 and bottomed at $3.5 million in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $5.9 million across 3 years, with a median of $5.2 million in 2023.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 72.85% — and 2025, when it tumbled 60.95%.
• Telix Pharmaceuticals' Other Non-Current Liabilities stood at $5.2 million in 2023, then jumped by 72.85% to $9.0 million in 2024, then sank by 60.95% to $3.5 million in 2025.
• Business Quant data shows TLX's Other Non-Current Liabilities at $3.5 million in Q4 2025, $9.0 million in Q4 2024, and $5.2 million in Q4 2023.